Abstracts tagged "Myositis"

Abstract Number: 0035 • ACR Convergence 2022
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
Rie Karasawa¹, James Jarvis², Toshiko Sato¹, Megumi Tanaka¹, Terrance P O'Hanlon³, Payam Noroozi-Farhadi⁴, Willy A. Flegel⁵, Kazuo Yudoh¹ and Lisa G Rider³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY, ³Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH, Garrett Park, MD
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory rheumatic diseases in children. Anti-endothelial cell antibodies (AECA)…
Abstract Number: 0167 • ACR Convergence 2022
Accuracy of Multi-Centric Local Determination of Anti-Synthetase Autoantibodies in Patients with Anti-Synthetase Syndrome and Other Autoimmune Diseases
Giovanni Zanframundo¹, Angela Ceribelli², Sara Faghihi Kashani³, Monica Morosini⁴, Sara Bozzini⁵, Natasa Isailovic⁶, Carlo Selmi⁷, Lorenzo Cavagna⁸ and Rohit Aggarwal⁹, ¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ²Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ³Stanford University, Stanford, CA, ⁴Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ⁵Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, ⁶IRCCS Humanitas Research Hospital, Rozzano (MI), Italy, Rozzano, Italy, ⁷IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, Rozzano, Italy, ⁸Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ⁹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: RNA-immunoprecipitation (RNA-IP) is considered the gold standard method for anti-tRNA synthetase antibodies (ARS-Ab) detection. This technique, however, is not widely available, unlike commercial kits,…
Abstract Number: 1660 • ACR Convergence 2022
Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality
Julie Paik¹, Caoilfhionn Connolly¹, Fredrick Wigley¹ and Laura Hummers², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Univerisity, Baltimore, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is poorly understood. The etiology of myopathy in SSc is heterogeneous and can result from an inflammation, disuse,…
Abstract Number: 1879 • ACR Convergence 2022
Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies
jiram torres-Ruiz¹, Abdiel Absalón-Aguilar², Juan Alberto Reyes-Islas², Alfredo Pérez-Fragoso², Nancy R Mejía-Domínguez³, guillermo Juárez-Vega⁴, Alejandro Alfaro-Goldaracena⁵, Beatriz Alcalá-Carmona², Guillermo Juárez-Vega³, Fabiola Cassiano-Quezada² and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico, ⁵Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Muscle atrophy is mediated by the ubiquitination of myofilaments by two ubiquitin ligases called Tripartite Motif Containing (TRIM) 63 and Atrogin-1, which are induced…
Abstract Number: 0041 • ACR Convergence 2022
Modeling Juvenile Dermatomyositis with Engineered Human Skeletal Muscle: Effects of Type I Interferonβ and Janus Kinase Inhibitors
Lauren Covert¹, George Truskey² and Jeffrey Dvergsten¹, ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Upregulation of Type I interferons (IFN I), including IFNβ, is a hallmark of adult and juvenile dermatomyositis (JDM), but its role in pathogenesis is…
Abstract Number: 0168 • ACR Convergence 2022
Semiquantitative Thigh Magnetic Resonance Imaging (tMRI) in Determining Skeletal Muscle Outcomes at Baseline and on Follow up in Idiopathic Inflammatory Myopathies (IIMs)
Mamatha Gorijavolu¹, Devender Bairwa², Chengappa Kavadichanda³, Sai Kumar Dunga⁴, Aishwarya Gopal⁵, Vir Singh Negi⁶ and Molly Thabah¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ³JIPMER, Pondicherry, Puducherry, India, ⁴Jawaharlal institute of postgraduate medical education and research, Srikakulam, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁶AIIMS Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Semiquantitative scoring of thigh Magnetic Resonance Imaging (tMRI) has shown contradictory results in associating muscle inflammation, damage, and clinically assessed muscle weakness. Moreover, there…
Abstract Number: 1730 • ACR Convergence 2022
T Cell-Macrophage Interactions Play a Critical Role in a Mouse Model of Histidyl-tRNA Synthetase-Induced Myositis
Daniel Reay¹, Ying Wang², Wael Jarjour³, Paula Clemens¹ and Dana Ascherman⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Miami Miller School of Medicine, Miami, FL, ³The Ohio State University, Columbus, OH, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Histidyl-tRNA synthetase (HRS) is a key target of antigen-specific B and T cell responses in the anti-synthetase syndrome. Despite a clear role for aberrant…
Abstract Number: 1880 • ACR Convergence 2022
Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys
Naveen R¹, Mrudula Joshi², Parikshit Sen³, Vishwesh Agarwal⁴, Samuel Shinjo⁵, Sinan Kardes⁶, James B. Lilleker⁷, Hector Chinoy⁸, Ashima Makol⁹, Oliver Distler¹⁰, Minchul Kim¹¹, Elena Nikiphorou¹², Ai Lyn Tan¹³, Babur Salim¹⁴, Tamer A Gheita¹⁵, Nelly Ziade¹⁶, Tsvetelina Velikova¹⁷, Tulika Chatterjee¹¹, Arvind Nune¹⁸, Marcin Milchert¹⁹, Ioannis Parodis²⁰, Abraham Edgar Gracia-Ramos²¹, Albert Selva O’Callaghan²², Miguel Angel Saavedra Salinas²³, Lorenzo Cavagna²⁴, Masataka Kuwana²⁵, Johannes Knitza²⁶, Jessica Day²⁷, Carlos Enrique Toro Gutiérrez²⁸, Carlo Caballero²⁹, Dzifa Dey³⁰, Erick Zamora Tehozol³¹, Jorge Rojas Serrano³², Ignacio Garcia-De La Torre³³, Iris Colunga³⁴, Javier Merayo-Chalico³⁵, John Pauling³⁶, Chris Wincup³⁷, Armen Yuri Gasparyan³⁸, Vikas Agarwal¹, Rohit Aggarwal³⁹ and Latika Gupta⁴⁰, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ³Maulana Azad Medical College, New Delhi, India, ⁴Mahatma Gandhi Missions Medical College, Lucknow, India, ⁵Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ⁶Istanbul University, Istanbul, Turkey, ⁷The University of Manchester, Manchester, United Kingdom, ⁸The University of Manchester, Sale, United Kingdom, ⁹Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ¹¹University of Illinois College of Medicine Peoria, Peoria, IL, ¹²Leiden University Medical Center & King's College London, London, United Kingdom, ¹³University of Leeds, Leeds, United Kingdom, ¹⁴Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹⁵Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁶Saint-Joseph University, Beirut, Lebanon, ¹⁷Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁸Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ¹⁹Pomeranian Medical University in Szczecin, Szczecin, Poland, ²⁰Karolinska Institutet, Stockholm, Sweden, ²¹Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²²Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²³IMSS, Ciudad de México, Mexico, ²⁴Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁶Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁷Walter and Eliza Hall Institute, Melbourne, Australia, ²⁸Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia, ²⁹Universidad del Norte, Barranquilla, Colombia, ³⁰University of Ghana School of Medicine and Dentistry, Accra, Ghana, ³¹Centro Medico Pensiones, Merida, Mexico, ³²Hospital Angeles Villahermosa, Ciudad de México, Mexico, ³³Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ³⁴Hospital Universitario UANL, Monterrey, Mexico, ³⁵Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ³⁶North Bristol NHS Trust, Bristol, United Kingdom, ³⁷Rayne Institute, University College London, London, United Kingdom, ³⁸Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ³⁹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴⁰Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Patients with comorbidities and active rheumatic disease have increased morbidity and hospitalization following SARS-CoV-2 infection. While vaccination has decreased this, many unknown factors still…
Abstract Number: 0117 • ACR Convergence 2022
Disparities in Prescription Medications Among Myositis Patients in a Large Urban Medical Center
Diala Alawneh¹, Zita Chan¹, William Galanter², John Berry³, Mina Al-Awqati⁴ and Huan Chang⁵, ¹University of Illinois at Chicago, Chicago, IL, ²University of Chicago, Chicago, IL, ³University of Illinois Hospital & Health Sciences System, Chicago, IL, ⁴University of Illinois, Chicago, IL, ⁵University of Illinois at Chicago and Jesse Brown VA Medical Center, Chicago, IL
Background/Purpose: Although women are twice as likely as men to develop myositis, Black women are affected disproportionately. Additionally, minorities with juvenile dermatomyositis are significantly more…
Abstract Number: 0169 • ACR Convergence 2022
Comparison of Diagnostic Criteria Sets in Diagnosing Antisynthetase Syndrome
Min-joo Ahn¹, Su-Jin Yoo², Seung-Cheol Shim², Seong Wook Kang² and Jinhyun Kim³, ¹Chungnam National University, Yuseong-gu, Daejeon, Republic of Korea, ²Chungnam National University Hospital, Daejeon, Republic of Korea, ³Chungnam National University Hospital, Jung-gu, Daejeon, South Korea
Background/Purpose: Anti-synthetase syndrome (ASS) is a distinct subset of idiopathic inflammatory myopathies (IIM), characterized by antibodies targeting an aminoacyl tRNA synthetase (ARS) along with clinical…
Abstract Number: 1856 • ACR Convergence 2022
Subclinical Coronary Artery Disease in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Evaluation by Computer Tomography Coronary Angiogram
Tsz Ho Luk¹, Weng Nga Lao¹, Steve Pang¹, Ho So², Tak Lung Wong³ and Yan Ki Tang⁴, ¹Kwong Wah Hospital, Hong Kong, Hong Kong, ²Chinese University of Hong Kong, Hong Kong, Hong Kong, ³KWH, Kowloon, Hong Kong, ⁴Kwong Wah Hospital, Hong Kong, China
Background/Purpose: Idiopathic inflammatory myopathy (IIM) poses elevated risk of cardiovascular event and mortality, similar to other autoimmune rheumatic diseases. With the use of computer tomography…
Abstract Number: 1881 • ACR Convergence 2022
Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals
Marina Pavía Pascual¹, Isidro Jarque Canalias¹, Jose Luis Morell², Jesús Loarce Martos³, Lorena Montaño Tapia⁴, Olga Rusinovich¹, Natalia de la Torre-Rubio¹, Maria Machattou¹, Pablo Navarro Palomo¹, Maria Carmen Barbadillo Mateos¹, Monica Fernandez Castro⁵, Blanca Garcia-Magallon¹, Maria Hildegarda Godoy Tundidor¹, Carolina Merino¹, JESUS SANZ SANZ¹, Jose Luis Andreu¹ and Jose Campos¹, ¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Puerta de Hierro Hospital, Madrid, Spain
Background/Purpose: Anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) antibody is robustly linked with malignancy-associated dermatomyositis (DM) in adults, but its specificity varies widely between series. TIF…
Abstract Number: 0151 • ACR Convergence 2022
Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study
Diana Gómez-Martín¹, jiram torres-Ruiz¹, victor Hugo Tovar-Méndez², Fabiola Cassiano-Quezada³, Daniel Alberto Carrillo-Vázquez⁴, Alfredo Pérez-Fragoso⁴, Nancy Mejía-Rodríguez⁵ and guillermo Juárez-Vega⁵, ¹INCMNSZ, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁵Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico
Background/Purpose: Risk factors associated with the development of infections in patients with idiopathic inflammatory myopathies (IIM) have not been fully addressed, particularly those related to…
Abstract Number: 0170 • ACR Convergence 2022
Minimal Clinically Important Difference in Myositis Response Criteria
Khushboo Singh¹, Sara Faghihi Kashani², Tissa Bijoy George³, Siamak Moghadam-Kia⁴, Dana Ascherman⁵, Rohit Aggarwal⁶ and Chester Oddis⁵, ¹UPMC McKeesport, Pittsburgh, PA, ²Stanford University, Stanford, CA, ³UPMC McKeesport, Monroeville, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: ACR/EULAR myositis response criteria were developed to assess the patient's disease activity, response to therapy, and long-term outcome as a standardized measure to be…
Abstract Number: 1857 • ACR Convergence 2022
Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic
Jennifer Hannah¹, Saadia Sasha Ali¹, Sloni Arora¹, John Cazabon¹, James Galloway¹ and Patrick Gordon², ¹King's College London, London, United Kingdom, ²King’s College Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Anti-MDA5 dermatomyositis is a clinical subtype of DM that is strongly associated with a rapidly progressive phenotype of interstitial lung disease resulting in a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].